A P-CAB which suppresses gastric acid by a more effective, differentiating mechanism of action compared to existing PPIs, has been developed by Onconic Therapeutics (A subsidiary company). Successfully completed Phase 3 clinical trial and under NDA by the Korean MFDS review for treatment of Erosive Esophagitis (EE). Clinical trials for new indication expansions are ongoing for treatment of gastric ulcer as well as prophylaxis for NSAID-induced peptic ulcer. A T2DM treatment in development by Jeil Pharmaceutical. Phase 1 study has been completed in Europe, and Phase 2 study is currently ongoing in South Korea.
A PARP/Tankyrase dual inhibitor in development by Onconic Therapeutics (A subsidiary company) for treatment of ovarian cancer in ongoing Phase 2 and pancreatic cancer in ongoing Phase 1b.
A novel small molecule for treatment of myocardial infarction. In preparation for a Phase 2 clinical trial in Korea.
Several active new drug development projects ongoing to target Inflammatory disease and various cancers and so on.